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Autoantibodies against C1q in Systemic Lupus Erythematosus
Are Antigen-Driven1
Monica Schaller,2* Cornelia Bigler,* Doris Danner,* Henrik J. Ditzel,†‡ and Marten Trendelenburg*§
Autoantibodies against complement C1q (anti-C1q Abs) were shown to strongly correlate with the occurrence of severe nephritis
in patients with systemic lupus erythematosus (SLE), suggesting a potential pathogenic role by interfering with the complement
cascade. To analyze the humoral immune response against C1q at the molecular level, we screened a bone marrow-derived
IgG/IgG Fab phage display library from a SLE patient with high anti-C1q Ab titer against purified human C1q. Six Fabs that
exhibited strong binding to C1q in ELISA were isolated. The anti-C1q Fabs recognized neoepitopes that were only exposed on
bound C1q and not present on soluble C1q mapping to different regions of the collagen-like region of C1q. Analysis of the genes
encoding the variable H and L chains of the IgG-derived anti-C1q Fab revealed that all the variable H and L chain regions were
highly mutated, with nucleotide and amino acid homologies to the closest germline in the range of 71–97% (average 85  4) and
72–92% (average 88 6), respectively. In addition, the variable region of the Fabs exhibited high replacement to silent ratios. The
six anti-C1q Fabs were shown to be of high affinity, with a Kd ranging from of 8.4  108 M to 1.4  107 M, comparable to an
antiviral immune response. Our data underlines the notion that the development of anti-C1q Abs in SLE is the consequence of
an Ag-driven, affinity-matured immune response. Those anti-C1q Fabs are unique tools to address how complement C1q is
implicated in the pathogenesis of SLE. The Journal of Immunology, 2009, 183: 8225–8231.
A n important hypothesis of the pathogenesis of sys-temic lupus erythematosus (SLE)3 assumes that thedisease is driven by a defective clearance of dead and
dying cells that could become antigenic and elicit autoimmunity
(1–5). The potential mechanism is based on the fact that mice
with defined single-gene defect leading to an altered clearance
of apoptotic cells develop severe autoimmunity with the occur-
rence of autoantibodies directed against nuclear components as
seen in SLE patients (6 –7). Lupus-prone mice were shown to
have an intrinsic impairment in apoptotic cell uptake (8) and
macrophages derived from the peripheral blood of SLE patients
also show defective uptake of apoptotic cells (9). In addition, a
number of lupus autoantigens in SLE were located on the sur-
face of apoptotic bodies and apoptotic blebs (10). Therefore,
apoptotic cell debris could be the source of autoantigens in
SLE. Indeed, the injection of apoptotic cells into healthy mice
could induce the production of autoantibodies (11) that were
directed against typical lupus Ags, including anti-nuclear, anti-
DNA, and anti-cardiolipin Abs.
In humans, the complement system has been shown to play an
important role in the clearance of apoptotic cells and deficiency of
one of the early components of the classical pathway of comple-
ment is strongly associated with the development of SLE. In fact,
homozygous deficiency of C1q, the first component of the classical
complement pathway, has been characterized as the strongest disease
susceptibility gene for SLE development in humans (12), although
most SLE patients do not have a primary complement deficiency.
Nevertheless, secondary hypocomplementemia of the classical path-
way is a frequent finding in SLE patients and often associated with the
occurrence of autoantibodies against C1q (anti-C1q Abs) (13–14).
Although anti-C1q Abs are known to occur in a number of distinct
autoimmune disorders, they are best described in patients with SLE
(15), wherein the occurrence of anti-C1q Abs was shown to strongly
correlate with active renal disease (16–20), suggesting that the anti-
C1q Abs are necessary, but not sufficient, for development of a pro-
liferative lupus nephritis (18–19, 21–24). In mice, Trouw et al. (25)
showed that anti-C1q autoantibodies deposit in glomeruli together
with C1q, but induced overt renal inflammation only in the context of
glomerular immune complex disease.
The origin of anti-C1q Abs remains to be identified, although im-
paired clearance of apoptotic material suggests the possibility that
C1q binding to the surface of apoptotic bodies renders it antigenic,
similar to nuclear components that are normally not exposed to the
immune system. In line with this hypothesis is the finding that anti-
C1q Abs are directed against a neo-epitope on the collagen-like region
(CLR) that is only exposed on bound C1q. Prolonged exposure of this
new epitope to the immune system, e.g., on the surface of incom-
pletely cleared apoptotic bodies, could incite an autoimmune response
against C1q. Recent studies also suggest that anti-C1q Abs are spe-
cific and that the occurrence of the Ab might be Ag-driven (18, 26–
27). To clarify this issue, we performed a detailed molecular analysis
of the human Ab response to C1q.
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Library construction and panning on C1q
For Ab selection, a phage library generated from total RNA of aspirated
bone marrow from an SLE patient was generated as described previously
(28, 29) and screened on human purified C1q (a gift from Bu¨hlmann
Laboratories, Scho¨nenbuch, Switzerland; 99% pure as judged by SDS
PAGE). C1q was coated overnight on ELISA plates at a concentration of
0.5 g/ml. In brief, phages resuspended in PBS containing 1% BSA were
incubated for 2 h at 37°C. Unbound phages were removed by washing 10
times with PBS containing 1% BSA. Bound phages, enriched for anti-C1q
bearing surface Fab, were eluted with 0.1 M glycine-HCl buffer (pH 2.2)
and immediately neutralized using 2 M Tris-base (pH 9.0). The eluted
phages were amplified by infection of Escheria coli and superinfected with
M13 helper phage. The panning procedure was repeated five times. Phage-
mid DNA was prepared from the last three panning rounds, and the gene
III fragment was then removed by restriction digest using enzymes NheI
and SpeI followed by religation. The reconstructed phagemid was used to
transform XL1-blue cells to produce clones secreting soluble Fabs. As
controls, two other bone marrow-derived IgG1 phage display libraries
were panned against C1q, one generated from a healthy individual and one
from an HIV-1 seropositive donor. Ab Fabs specific for measles virus were
previously isolated from the library of the healthy individual (30) and Ab
Fabs specific for HIV-1 gp120 were previously isolated from the library of
the HIV-1 donor (31). Further, as a control for the integrity of the HIV-1
Ab library, the same library was also panned against HIV-1 gp120.
Production and purification of anti-C1q Fabs
Fabs were purified from bacterial supernatants by affinity chromatography.
E. coli containing the appropriate clone were inoculated overnight at 37°C
into 100 ml cultures of super broth medium containing ampicillin (50 g/
ml) and tetracycline (10 g/ml). From this overnight culture, 1 ml was used
to inoculate 100 ml of super broth containing ampicillin (50 g/ml), tet-
racycline (10 g/ml), and MgCl2 (20 mM) and then incubated at 37°C with
shaking until the OD600 was 0.9. Thereafter, protein expression was in-
duced overnight by addition of 1 M isopropyl -D-thiogalactopyranoside
at a final concentration of 1 mM and 4 M cyclic AMP at a final concen-
tration of 0.4 mM. The following day, the cultures were centrifuged at 7000
rpm and the bacterial pellets resuspended in 1 PBS containing 0.5 mM
PMSF, filtered, sonicated, centrifuged again at 17,000 rpm, and the super-
natant loaded onto a column of goat-anti-human F(ab)2 IgG Ab coupled to
protein G CNBr-activated Sepharose 4B (Amersham Biosciences). After
washing, bound Fabs were eluted at pH 3.3 using 100 mM citric acid,
neutralized with 1M Tris (pH 9.0), and dialyzed against PBS (pH 7.2). The
degree of purity of the anti-C1q Fab preparations was confirmed by SDS
PAGE analysis (12% Tris Gel; Bio-Rad) and silver staining (Amersham
Biosciences). Reactivity with purified human C1q but not with control Ags
was confirmed by Western blot analysis and ELISA.
ELISA
C1q specificity. The serum of the SLE patient from whom the phage li-
brary was obtained was analyzed for the presence of anti-C1q Abs using a
commercially available test (Bu¨hlmann Laboratories) according to the
manufacturer’s instructions and as described previously (24, 32).
Competition with soluble C1q. To assess the specificity of the anti-C1q
Fabs derived from phage display, we screened the purified Fabs in an
ELISA against human plate-bound C1q. All six anti-C1q Fabs at a con-
centration of 0.5 g/ml were preincubated with either 0, 2, or 4 g soluble
C1q before incubation (estimated molar ratios of Fab to C1q were 1:4.4 and
1:8.8, respectively) on a microtiter plate coated with C1q before further
processing. For this procedure, C1q was coated onto Costar microtiter
plates in carbonate buffer (0.2 M NaHCO3 and 0.2 M Na2CO3), pH 9.6, at
a concentration of 0.5 g/well in a total volume of 100 l overnight at 4°C.
Next, the microtiter plates were washed five times with PBS-0.05% Tween 20
and then incubated with 3% BSA blocking solution for 1 h at 37°C. The
purified anti-C1q Fabs, a 1/50 dilution of a control serum from a SLE patient
previously shown to have high anti-C1q titers, a healthy control serum, and
unrelated Fab b12 (specific for gp120 of HIV-1 (IIIB strain)) were incubated
in high salt buffer (1 M NaCl, 1% FCS, 0.05% PBS-Tween 20) with the test
Ags for 2 h at 37°C followed by five washing steps with PBS-0.05% Tween
20. High salt conditions were used to avoid cross-reactivity of immune com-
plexes to C1q for the control sera. Detection of bound human Fabs and mouse
Ab was conducted with alkaline phosphatase-labeled goat anti-human IgG
F(ab)2 Ab (Jackson ImmunoResearch Laboratories) diluted 1/500 (1 g/ml)
in 1% PBS-BSA for 1 h at 37°C and visualized with nitrophenol substrate
(Sigma-Aldrich) by reading absorbance at 405 nm.
Cross-reactivity of anti-C1q Fabs. Cross-reactivity of all six human anti-
C1q Fabs (0.5 g/ml) was assessed toward human placental dsDNA (Sig-
ma-Aldrich), collagen type I (Calbiochem), collagen type IV, and BSA
(both from Sigma-Aldrich), which were coated onto Costar microtiter
plates in PBS at a concentration of 0.5 g/well in a total volume of 100 l
overnight at 4°C or overnight at 37°C in 1% BSA (DNA), after which the
ELISA was performed as described above. Reactivity toward nucleosomes
was tested using a commercially available kit from Orgentec Diagnostika
and the same secondary Abs as used for the other Ags tested. As control,
an anti-C1q-positive SLE serum and a healthy control serum in a 1/50
dilution in high salt buffer and unrelated Fab b12 (0.5 g/ml) were also
tested on those Ags. As positive controls for the different coatings, we
tested in the same ELISA SLE patient serum with a high anti-DNA titer,
as well as rabbit-anti-human alkaline phosphatase-labeled anti-collagen
type I Ab, anti-collagen type IV Ab, and anti-BSA Ab, all of which tested
highly positive for their respective Ags (data not shown).
Nucleic acid sequencing
Phagemid DNA was extracted using a DNA extraction kit (Qiagen) and
directly sent to Microsynth for sequencing analysis. Sequences were then
compared with most homologous germline genes in the NBCI Ig Blast
GenBank program (http://www.ncbi.nlm.nih.gov/igblast), IMGT database
(http://imgt.cines.fr), and VBLAST (http://vbase.mrc-cpe.cam.ac.uk).
Generation of CLR and globular heads (GH) of C1q
For the generation of CLR, 200 g of C1q were first dialyzed against sodium
acetate buffer (pH 4.45) at 4°C overnight before digestion with 14g of pepsin
(Sigma-Aldrich) for 20 h at 37°C, as described previously (32). The digest was
then centrifuged for 20 min at 35,000 g and the supernatant applied on a size
exclusion column (Superdex 200 10/300 GL; Amersham Biosciences) using
fast protein liquid chromatography for the separation of CLR.
For the generation of GH, 200 g of C1q were incubated with 800 g
of collagenase (Sigma-Aldrich) for 16 h at 37°C and centrifuged at 14,000
g for 10 min at 4°C. Separation of GH form collagenase and undigested
C1q was then performed using fast protein liquid chromatography and a
size exclusion column (Superdex 200 10/300 GL, Amersham Biosciences).
The protein concentrations of CLR and GH in the collected fractions were
assessed by NanoDrop 1000 spectrophotometer (Witec) at OD280 nm and
the degree of purity of both protein preparations were confirmed by SDS
PAGE (12% Tris gel; Bio-Rad) followed by silver staining (Amersham
Biosciences). The reactivity with the six purified human anti-C1q Fabs was
tested on ELISA as described above by coatings of similar amounts of C1q,
CLR, or GH. Unrelated Fab b12, specific for gp120 of HIV-1 (IIIB strain),
served as a negative control.
Western blot analysis
Human purified C1q (1 g), under nonreducing and reducing conditions (final
concentration of 0.1 M DTT), was mixed with 5 sample buffer (Pierce),
adjusted to a final volume of 15 l with distilled water, and boiled for 5 min
at 95°C before being loaded on a 12% SDS-PAGE HCl-Tris gel (Bio-Rad).
The proteins were then electroblotted onto nitrocellulose membrane (Bio-Rad)
and blocked (5% nonfat dry milk in 0.05% Tween 20 PBS) for 1 h before
overnight incubation at 4°C with 1 g/ml purified anti-C1q Fabs in blocking
buffer. After repeated washing of the nitrocellulose membrane (6  5 min),
bound Ab was detected with HRP-labeled F(ab)2 of goat anti-human F(ab)2-
specific Ab (1:5000, Serotec) incubated for 1 h and visualized by chemilumi-
nescent substrate (ECL; Amersham Biosciences) and autoradiographic film
(CL-Xposure; Sigma-Aldrich). Control staining of immunoblots omitting the
primary Ab was included (data not shown).
Affinity measurements of anti-C1q Fabs by ELISA
CLR was first incubated with the anti-C1q Fabs at a constant concentration
until equilibrium was reached. The concentration of free Abs was then
determined by an inhibition ELISA. Briefly, CLR was preincubated sepa-
rately at various concentrations (2 1010 M to 2 107 M) in carbonate
buffer (0.2 M NaHCO3 and 0.2 M Na2CO3), pH 9.6, with each of the six
anti-C1q Fab at its equilibrium concentration in the range of 2–5  107
M. After 2 h at 37°C, the mixture was incubated onto a microtiter plate
previously coated with 0.5 g/well CLR (coating as described above for
C1q) and blocked with 3% BSA for 2 h at 37°C. After washing, bound
Fabs were detected using an anti-F(ab)2 alkaline phosphatase-labeled Ab
(Jackson ImmunoResearch Laboratories) and the absorption read at 405
nm. The Kd for each anti-C1q Fab could then be calculated using Scatchard
plot analysis (Prism graph version 4.1; GraphPad Software).
8226 MOLECULAR PROFILE OF ANTI-C1q AUTOANTIBODY REPERTOIRE IN SLE










Cloning of human IgG autoantibodies to C1q
To analyze the humoral immune response against C1q, we
screened an IgG1/IgG Fab phage-display library of 4  108
members generated from aspirated bone marrow of an SLE patient.
The serum was shown to contain high anti-C1q Ab titer (74 U/ml,
norm 15). In concordance with the standard clinical method for
determining anti-C1q, the patient’s Ab library was screened
against purified human C1q coated onto ELISA plates in the pres-
ence of 1 M NaCl to avoid low-affinity binding (33). After five
rounds of selection, a 1000-fold amplification of the IgG phage-
display library (2.8  106 size) and a 100-fold amplification of the
IgG Fab phage-display library (0.3  104 size) in eluted phages
were observed, indicating enrichment for Ag-binding clones. Con-
trols consisted of two bone marrow-derived IgG1 phage display
libraries, one generated from a healthy donor (30) and one from a
HIV-1 seropositive donor (33). With the control libraries, no en-
richment in eluted C1q specific phages was observed and the
phage titers declined with each round of selection. In contrast,
when the Ab library from the HIV-1 positive donor was selected
on HIV-1 gp120 in parallel, the phage titers increased 10,000-fold
(supplemental Table S1).4
ELISA screening of supernatants from 60 clones from the fourth
and fifth rounds of selection with the SLE library yielded six Fabs that
exhibited strong binding to human C1q. As described for serum anti-
C1q Abs from SLE patients (33, 34), the anti-C1q Fab binding was
specific for plate-bound C1q because preincubation of the purified
anti-C1q Fab with excess liquid phase C1q did not lead to any sub-
stantial reduction of the binding to plate-bound C1q (Fig. 1).
Specificity of the monoclonal anti-C1q Fabs
To specify the epitope on C1q recognized by human autoantibody
Fabs, C1q was digested either with pepsin to obtain the N-terminal
CLR or with collagenase to obtain the C-terminal GH region of
C1q. The CLR or GH region fractions were then purified over a
size exclusion column and coated onto ELISA plates. Interest-
ingly, CLR was recognized equally well as the undigested C1q,
with three (A4, A6, and B8) of the six anti-C1q Fabs tested show-
ing an ever higher signal on CLR than on undigested C1q, whereas
binding to the GH was not observed for any of the anti-C1q Fabs
(Fig. 2A). Control sera obtained from healthy individuals showed
weak reactivity with C1q or digested fractions of C1q, whereas
control serum from a SLE patient recognized C1q and CLR but not
GH. Finally, heat-aggregated IgG bound C1q and GH as expected,
but not CLR (Fig. 2A). To further assess specificity, we tested all
six anti-C1q Fabs for reactivity to human placental dsDNA, col-
lagen type I and type IV, BSA, and nucleosomes by ELISA (Fig.
2B). As seen in Fig. 2B, no cross-reactivity of the tested Ags was
observed for any of the anti-C1q Fabs. Absorbances at 405 nm
were similar to negative controls, consisting of a healthy serum
and unrelated HIV-1-specific Fab b12 tested in the same assay. To
determine whether the six human anti-C1q Fabs differ in their rec-
ognition of the three similar, but distinct, polypeptide chains of the
C1q (A, B, and C), products of three distinct genes aligned in the
same orientation (A-B-C) on a 24 kb stretch of DNA on chromo-
some 1p (35), we performed a Western blot assay (supplemental
Fig. S1). The epitope recognized by the six Fabs is at least partly
linear and involves conserved epitopes present on at least two of
the three polypeptide chains of the C1q molecule.
Human anti-C1q Abs results from an Ag-driven response
To determine whether human Abs to C1q evolved as a result of an
Ag-driven immune response, we compared the genes encoding the
variable heavy and light chains of the IgG-derived anti-C1q Fabs
with the closest germline sequences in the GenBank, IMGT, and
VBASE databases (Fig. 3). All the variable H and L chain genes
of the anti-C1q Fabs were highly mutated, with nucleotide and
amino acid homologies to the closest variable H chain (VH) germ-
line genes in the range of 71–92% (average 81%) and 72–92%
(average 82%), respectively (Table I) and to the closest variable L
chain (VL) germline genes in the range of 92–97% (average 94%)
and 85–91 (average 88%), respectively (Table I). Additionally, the
VH and VL chain genes exhibited a high replacement to silent
mutation ratio (R:S) for the CDR1 and CDR2 compared with the
framework region (FR) 1, FR2, and FR3 (Table I) for all Fabs
(with the exception of Fab A8), which is characteristic of an af-
finity-matured Ab response (36–46). The two Fabs A4 and A14,
which exhibited the strongest binding to C1q (Fig. 1), had the
highest R:S ratio for the CDRs compared with the other anti-C1q
Fabs. Additionally, these clones exhibited a substantially higher
R:S ratio for the CDRs compared with their FRs (Table I). Strong
binding to C1q was seen when the deduced amino acid homologies
to the closest germline were around 83%, such as that seen in
anti-C1q Fab A4, A14, and C8 (Fig. 1). The sequence analysis of
the H chain also showed that the three Fabs (A4, A14, and B8) had4 The online version of this article contains supplemental material.
FIGURE 1. Anti-C1q Fabs recog-
nize plate-bound C1q only. Bars repre-
sent the acquired absorbance at 405 nm
of the six human monoclonal anti-C1q
IgG-Fabs (A4, A6, A8, A14, B8, and
C8) binding to plate-bound C1q after
preincubation with either no (f), 2 (),
or 4 (o) g of soluble C1q by compe-
tition ELISA. Fabs were tested at a con-
centration of 0.5 g/ml under high salt
conditions. Binding of the six anti-C1q
Fabs were in the range of serum from a
patient with SLE, with a high titer of
anti-C1q Abs as determined previously
and substantially above absorbance val-
ues of unrelated anti-HIV-1 gp120 Fab
b12 and normal human serum (NHS),
which served as positive and negative
controls, respectively.
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closely related sequences, which were likely somatic variants that
had evolved from a common ancestor. Interestingly, one anti-C1q
Fab A8 had a much higher R:S mutation rate of the FR when
compared with the CDRs, which is unusual for an Ab exhibiting
high affinity for its Ag. Therefore, mutations in the CDR must be
the major contributor to the C1q affinity.
The junction JH and JL genes of the anti-C1q Fabs were also
highly mutated and exhibited nucleotide homologies to the closest
FIGURE 2. Determination of the
specificity of the six human monoclo-
nal IgG-Fabs by ELISA. A, Bars rep-
resent the acquired absorbance at 405
nm for binding of IgG-Fabs (1 g/ml)
to undigested C1q, CLR, and GH. As
controls, serum from a SLE patient,
heat-aggregated IgG (HAGG) gener-
ated from a healthy donor, and nor-
mal human serum (NHS) from a
healthy donor were used. B, Reactiv-
ity of the six monoclonal human IgG-
Fabs (1 g/ml) against unrelated Ags
(coated at 5 g/ml), namely human
placental dsDNA (dsDNA hp), colla-
gen type I and type IV, BSA, and nu-
cleosomes was assessed by measur-
ing the absorbance at 405 nm by
ELISA. None of the anti-C1q IgG-
Fabs cross-reacted with the Ags
tested and were in the range of the
absorbance signal of unrelated anti-
HIV-1 gp120 Fab b12 and serum
from a healthy donor used as con-
trols. As a positive control, serum
from a SLE patient known to be
positive for anti-DNA autoantibod-
ies was included in the assay.
FIGURE 3. Alignment of the amino acid sequence of each anti-C1q variable heavy (A) and variable light (B) domains of the anti-C1q Fabs to their
closest germline sequence. All six anti-C1q IgG Fabs cloned from a SLE patient were highly somatically mutated. Residues believed to have arisen from
somatic mutations (deduced from comparison to the closest germline sequence) are in red, indicating an amino acid that is altered in the anti-C1q Fab protein
sequence. Fabs are grouped according to the closest V gene alignment.
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JH and JL germline genes in the range of 60–72% (average 66%).
The identification of the closest D segment proved even more dif-
ficult due to significant somatic modifications in the range of 60–
80% (average 70%). The closest J and D germline genes alignments,
as presented in Table I, could only be found by using less stringent
conditions because only a few nucleic acids or short stretches of nu-
cleic acids were homologous to the anti-C1q Fabs (no significant
score) when analyzed with the different Ig databases.
Comparison of the relative affinity of the panel of anti-C1q Fabs
Autoantibodies involved in an active immune response generally
exhibit high affinity for their Ag. To evaluate the affinity of the
anti-C1q Fabs, we tested all six anti-C1q Fabs in an inhibition
ELISA wherein the binding of all Fabs to plate-bound CLR was
inhibited by preincubation with increasing concentrations of sol-
uble CLR. The absorbance at 405 nm represents the concentration
of free anti-C1q Fabs able to bind to plate-bound CLR used to
calculate the percent inhibition of maximum binding (Fig. 4). As
described by Friguet et al. (47), this inhibition ELISA allows cal-
culation of the Kd using Scatchard plot analysis. Affinities assessed
in such a way were very similar for all six anti-C1q IgG Fabs in the
range of 8.4  108 M to 1.4  107 M (individual Kd values are
depicted in Table II). Although those results are relative affinities,
it is important to note that the strength of the immune response of
those autoreactive monoclonal anti-C1q Fabs is in the range of an
anti-viral immune response (108 M). Taken together, the high
degree of somatic mutation, high R:S ratios, and interclonal vari-
ants and the affinities, as assessed by Scatchard plot analysis and
sustained high salt conditions, strongly suggest that the described
human monoclonal anti-C1q Abs are derived from B cells in-
volved in an Ag-driven, affinity-matured immune response.
Binding of anti-C1q Abs to C1q relays not only on
charge-charge interactions
The binding of anti-dsDNA Abs to dsDNA has been found to be
associated with the enrichment of arginine residues in the CDR3 of
the H chain of these Abs. Because C1q is a basic protein, we
analyzed whether the Fabs or each of their CDR and FR of the six
anti-C1q Fab Abs were enriched for acidic residues to determine
whether binding of the anti-C1q Fab Abs to C1q relied only on
charge-charge interactions. Interestingly, no enrichment of acidic res-
idues was observed. Further, the six anti-C1q Fab Abs exhibited a
wide range of isoelectric points (3.1- 9.5) for the entire Fab domain as
well as for the individual CDR and FR (Table S1). Additionally, no
correlation between the individual affinity constant of the six anti-C1q
and their respective isoelectric points was observed. Together, these
FIGURE 4. Relative affinities of the panel of six anti-C1q Fab toward
CLR as measured by inhibition ELISA. Anti-C1q IgG Fab at a constant
concentration of 2.5  107 M were preincubated without CLR (100%
maximum binding) or with serial dilutions of CLR (2–10  107 M)
before adding to microtiter plate coated with CLR. By measuring the ab-
sorbance at 405 nm, we calculated the amount of inhibition of binding to
plate-bound CLR with increasing amounts of soluble CLR concentration.
As an internal control, absorbance of the anti-HIV-1 Fab b12 on recom-
binant gp120 was measured the same way and its affinity recalculated.
Affinities of the six human anti-C1q IgG-Fabs were in the range of 8.4 
108 M to 1.4 107 M as assessed by Scatchard plot analysis. Individual
values for each anti-C1q Fab are depicted in Table II.
Table I. Comparison of the nucleotide and deduced amino acid sequences of the anti-C1q Fabs with the closest germline sequences for the VH and
VL chains




Homology (%) R:S Ratio FR R:S Ratio CDR Closest D Germline Closest J Germline
VH chain
A4 VH2–26*01 86.5 91.5 8:3  2.6 9:1  9 DH2–24*01 JH6*01
A14 VH2–26*01 85.9 90.6 4:6  0.8 9:1  9 DH6–19*01 JH4*03
B8 VH2–26*01 92.4 91.8 4:8  0.5 5:2  2.5 DH3–10*02 JH6*01
A6 VH2–5*01 78.2 70.6 18:4  4.5 8:1  8 DH3–16*02 JH6*02
A8 VH3–20*01 71.7 88.4 26/2  13 9:2  4.5 DH1–26*01 JH6*01
C8 VH4–4*07 85.3 92.0 16:6  2.6 7:2  3.5 DH5–24*01 JH5*02
VL chain
A4 Vk1D-13*01 91.0 97.0 6:2  3 5:1  5 NA JkV3D*01
A14 Vk1D-13*01 87.0 95.7 6:2  3 4:1  4 NA Jk2*04
B8 Vk1D-13*01 90.0 95.5 2:4  05 3:1  3 NA Jk2*02
A6 Vk1D-13*01 85.5 94.5 9:3  3 6:2  3 NA Jk3*02
A8 Vk2–24*01 89.8 95.5 7:4  1.7 4:1  4 NA Jk3*01
C8 VL11–55*01 89.0 92.0 8:4  2 6:2  3 NA JL1*01
NA, Not applicable.
Table II. Relative affinities (KD) as measured by Scatchard plot
analysis
Clone KD values
A4 5.16  108
A14 8.35  108
B8 4.72  107
A6 1.40  107
A8 7.80  107
C8 5.20  107
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data indicate that the binding of the anti-C1q Fab Abs to C1q is not
based on charge-charge interactions alone, but that conformational
structures, such as protein motifs, likely also play a role.
Discussion
In this study, we have shown that human anti-C1q Abs derived from
the bone marrow of a SLE patient arise as a result of an Ag-driven
immune response. This observation supports the view that comple-
ment C1q is implicated in the pathogenesis of the disease. This hy-
pothesis is primarily based on the observation that most patients with
C1q deficiency develop a lupus-like syndrome (15, 48), with homozy-
gous C1q deficiency being the strongest susceptibility gene for the
development of SLE despite the fact that most SLE patients do not
show a primary complement deficiency. Nevertheless, secondary hy-
pocomplementemia is a frequent finding in SLE patients due to the
consumption of early components of the classical pathway of com-
plement, including C1q (13–14, 49). The reason for this consumption
is not fully understood, but may partially be explained by the detec-
tion of anti-C1q Abs in 20–50% of unselected SLE patients and
more than 95% of patients with severe lupus nephritis. Although anti-
C1q cannot account for hypocomplementemia in all patients with
SLE, there is a strong correlation between the occurrence of these
autoantibodies and hypocomplementemia (13, 23, 50). An increasing
number of studies suggest a pathogenic role of anti-C1q Abs in SLE,
particularly in the development of proliferative lupus nephritis (24,
51), because anti-C1q Abs strongly correlate with renal flares (52).
In contrast to many other autoantibodies described in SLE, anti-
C1q Abs are directed against a highly functional molecule. It has been
shown that C1q, as the first molecule of the classical complement
pathway, plays an important role in the clearance of immune com-
plexes and apoptotic cell debris (11–12, 53). Anti-C1q Abs may alter
the physiological role of C1q by occupying important binding sites for
C1q receptors and thus might interfere with the process of cell lysis
and uptake of immune complexes and apoptotic bodies.
To characterize the anti-C1q Abs response on a molecular level, we
screened a human IgG-IgG Fab phage-display library and retrieved
six anti-C1q Fabs. All Fabs showed the typical characteristics re-
ported previously (13, 18, 26, 33–34, 50, 54): high specificity even
under high salt conditions for the CLR of plate-bound C1q but not for
soluble C1q. These binding characteristics are thought to occur due to
the expression of neoepitopes on C1q in its bound form (51, 55).
Concordant with this hypothesis are our findings in Western blot as-
say wherein different C1q polypeptide chain recognition patterns were
observed for the six anti-C1q Fabs tested, suggesting involvement of
different epitopes on C1q (supplemental Fig S1). The fact that we
could generate multiple specific Abs to C1q from the SLE patient
library, with high affinities and within the range of other human Abs
as well as human anti-viral Abs (40, 56), provides evidence for an
immune response actively driven by bound C1q. Bone marrow was
used as source for the phage libraries, as it is a major repository for
plasma cells producing Abs, broadly reflecting the repertoire found in
serum (57, 58). Unless the donor has reasonable numbers of specific
plasma or B cells and corresponding serum Abs titers, specific high-
affinity human Abs cannot be cloned from the small immune libraries
generated from patients like the one we have screened. As indicated
by the comparison of the genetic diversity of the six anti-C1q Fabs
(Table I), we are confident that we have selected a representative
panel of anti-C1q Abs from the bone marrow of this SLE patient. The
anti-C1q Fabs showed extensive somatic mutation, with high R:S ra-
tios in the CDRs. As shown previously for autoantibodies of patho-
genic relevance, the immune response is characterized by a high de-
gree of somatic hypermutation in the Ig genes during B cell
maturation (33, 59, 60). Autoantigens, as has been shown for DNA,
can trigger B cell responses by simultaneously activating B cell Ag
receptor and TLR signaling pathways leading to potent B cell re-
sponses such as B cell maturation (10). Thus, the high R:S ratio and
overall somatic mutations of the anti-C1q Fab clearly show that they
were produced as a result of an affinity-matured immune response.
It has been shown that the appearance of self-reactive Abs in SLE
precedes renal flares but the point in the B cell pathway where toler-
ance is first broken has not been defined. In line with the findings of
Yurasov (61), who found that the Ag-driven IgM immune response
toward C1q in SLE patients seemed to be biased toward use of a
restricted VH repertoire, we found IgG Fabs belonging to the gene
families VH3, VH4, and VH2. It is interesting to note that four of the
six anti-C1q IgG Fabs belong to the VH2 gene family, which has
rarely been reported in that context. Along with the observed in-
creased somatic hypermutation, this is consistent with findings that
Ag selection pressure along with VL receptor editing might shape the
Ig repertoire differently in autoimmune disease compared with healthy
controls (59, 62–64). Nevertheless, the factors that lead to this appar-
ent abnormal B cell tolerance accounting for B cell maturation and
affinity selection remain to be explored.
In conclusion, our analyses of human bone marrow-derived anti-
C1q Fabs generated from the B cell repertoire of a SLE patient
suggest that the development of anti-C1q Abs is the consequence
of an Ag-driven immune response. This observation supports the
hypotheses that both complement C1q and the process of affinity
maturation of autoantibodies in general are implicated in the
pathogenesis of the disease. The generated monoclonal Fabs will
be an excellent tool for further studies on the epitope and the role
of anti-C1q Abs in the pathogenesis of SLE.
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Fig. SI. Epitope characterization of the human anti-C1q Fabs. All anti-C1q Fab fragments recognized at least 2 of the 3 polypeptide
chains of C1q.  (A) SDS-PAGE gel separation of full-length C1q showing the similar but distinct patterns of the 3 polypeptide chains A, B and C
under non-reducing (NR) and reducing (R) conditions after silver staining. The C1q molecule is composed of 3 similar, but distinct, polypeptide
chains, A, B and C, which are the product of three distinct genes aligned in the same orientation in the order of A-B-C on chromosome 1p. Under
non-reducing conditions A-B and C-C chain dimers are formed, whereas under reducing conditions all three polypeptide chains are  separated.
(B) Purified anti-C1q IgG-Fab fragments (2g/ml) were tested for binding to C1q under non-reducing (NR) and reducing (R) conditions in
Western blot analysis. The table below the blots summarizes the polypeptide chain recognized, bold indicating a strong recognition signal.
Interestingly, all the anti-C1q Fabs recognized at least two different polypeptide chains. Fabs A4, A6 and A14 recognized all three polypeptide
chains under both non-reducing and reducing conditions, whereas the binding seemed to be weaker for Fab A6 compared to Fab A4 and A14.
Fab B8 recognized the A-B dimer strongly, but the C-C dimer only weakly under non-reducing conditions, whereas only the A and B chain
bound under reducing conditions. Fabs A8 and C8 bound only the A and B under reducing condition and not the C polypeptide chain. These
observations indicate that the epitope recognized by the 6 Fabs is at least partly linear and involves conserved epitopes present on at least two of
the three polypeptide chains of the C1q molecule.
 Table S1. pI values of the different human anti-C1q Fabs and each of 
their CDR and FR regions.  
 
 
  Fabs CDR1 CDR2 CDR3 FR1 FR2 FR3 
         
Heavy-chain A4 4.1 6 10.8 4.1 6.3 10.9 8.9 
 A6 3.1 6.1 9.4 3.1 9.1 10.1 9.5 
 A8 9.5 3.1 4.1 9.5 3.8 6.3 9.9 
 A14 6.9 6.1 10.9 6.9 8.9 10.9 8.9 
 B8 6.3 3.3 7.7 6.3 7.1 10.1 9.5 
 C8 3.7 5.8 9.7 3.7 3.1 10.1 8.9 
         
Light-chain A4 4.4 11.1 3.0 7.7 6.1 10.2 3.7 
 A6 4.4 1.9 3 10.1 6.1 10.4 4.3 
 A8 3.0 4.9 11.4 6.6 5.3 9.8 3.4 
 A14 4.4 6.9 3 5.9 6.1 10.4 4.3 
 B8 4.3 6.1 3 5.8 6.1 10.4 4.3 































Table S2. Titers of eluted phage of consecutive rounds of selection.  
   
 
 HIV-C1q (1) HIV-gp120 (+1) NC-C1q (2) 
    1.0 x 10
8
        1.0  x 10
8





 3.2 x 10
4
 4.0 x 10
5





 2.6 x 10
3
 1.6 x 10
7





  < 1  1.9 x 10
9










HIV-C1q designates that the HIV-1 patient-derived phage library was panned on C1q, 
HIV-gp120 designates that HIV-1 patient-derived phage library was panned on gp120, NC-
C1q designates the healthy individual-derived phage library was panned on C1q. nd=not 
deterimined 
 
 
 
